BioMarin Pharma (BMRN) Announced Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB)
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it presented interim data from a Phase 1/2 trial for BMN 250 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
